scorecardresearch
AstraZeneca to acquire US-based Alexion for $39 billion

AstraZeneca to acquire US-based Alexion for $39 billion

Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares per Alexion share, the company said

Astrazeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a $39 billion deal, the company said in a statement on Saturday.

Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares per Alexion share, the company said.

Also read: Sputnik V to AstraZeneca: 'Combine your vaccine with ours to boost efficacy'

Also read: AstraZeneca to test combining coronavirus vaccine with Sputnik V shot